Author:
Chupp Geoffrey,Lugogo Njira L.,Kline Joel N.,Ferguson Gary T.,Hirsch Ian,Goldman Mitchell,Zangrilli James G.,Trudo Frank
Subject
Pulmonary and Respiratory Medicine,Immunology and Allergy,Immunology
Reference17 articles.
1. MEDI-563, a humanized anti-IL-5 receptor alpha mAb with enhanced antibody-dependent cell-mediated cytotoxicity function;Kolbeck;J Allergy Clin Immunol,2010
2. Fasenra™ (benralizumab) [prescribing information],2017
3. Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting beta2-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial;Bleecker;Lancet,2016
4. Benralizumab, an anti-interleukin-5 receptor alpha monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial;FitzGerald;Lancet,2016
5. Oral glucocorticoid-sparing effect of benralizumab in severe asthma;Nair;N Engl J Med,2017
Cited by
18 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献